CLINICAL TRIALS

InSightec ExAblate Uterine Fibroid V2 System for the Treatment of Symptomatic Uterine Fibroids

The purpose of this study is to gain FDA approval of the new generation of the ExAblate system, ExAblate UF V2 System, for the treatment of symptomatic uterine fibroids*.   ExAblate MRgFUS system has been commercially available in the US to treat symptomatic fibroids for the last 9 years.   While similar to the commercial system, the ExAblate UF V2 device includes changes which are intended to enhance further the device performance and safety.

ADDITIONAL DETAILS HERE…

 

 

 

Stanford University Medical Center
Stanford, California, USA
Fizaa Ahmed
(650) 725-6409
fizaa@stanford.edu

   


Brigham and Women’s Hospital
Boston, Massachusetts, USA
Louise Greenberg
(617) 732-5441
lgreenberg@partners.org

 

Please consult ClinicalTrials.gov for the full list of centers:
http://www.clinicaltrials.gov/ct2/show/NCT01285960?term=ExAblate+2100+UF&rank=2
 

University of Virginia Health System